Bietti's crystalline corneoretinal dystrophy (BCD) is a recessive degenerative eye disease caused by germ-line mutations in the CYP4V2 gene. More than 80% of mutant alleles consist of three mutations; two splice site alterations and one missense mutation, viz, c.992C>A translating to p.H331P. In the present study, we analyzed the expression of CYP4 family members in human tissues and conducted functional studies with the wild-type and p.H331P enzymes to better understand the link between CYP4V2 activity and BCD. Expression analysis of 17 CYP1-4 genes showed CYP4V2 to be a major P450 in ARPE-19 cells, a human cell line spontaneously generated from normal human retinal pigment epithelium, and the only detectable CYP4 transcript. Immunohistochemical analysis demonstrated that CYP4V2 protein was present in epithelial cells of the retina and cornea, and that the enzyme was localized to endoplasmic reticulum. Recombinant reconstituted CYP4V2 protein metabolized eicosapentaenoic acid and docosahexaenoic acid, the latter an important constituent of the retina, to their respective ω -hydroxylated products at rates similar to purified CYP4F2, an established hepatic PUFA hydroxylase. The disease-associated p.H331P variant was undetectable by Western blot in HepG2 cells stably transduced with lentiviral expression vectors. Finally, over expression of functional CYP4V2 in HepG2 cells alters lipid homeostasis. Therefore, we have demonstrated that CYP4V2 protein is expressed at high levels in ocular target tissues of BCD, that the enzyme is metabolically active towards PUFAs and that the functional deficit in BCD patients carrying the H331P variant is most likely a consequence of the instability of the mutant protein.
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Introduction
Bietti's crystalline corneoretinal dystrophy (BCD) is an autosomal recessive degenerative retinopathy clinically characterized by progressive decline in central vision, night blindness and constriction of the visual field. The average age of manifestation in affected family members is around 30 years (Hu 1983) . Morphologically, BCD is defined by yellow-white crystalline lipid deposits in the retina and the cornea (Bietti 1937) , ultimately leading to degeneration of the retina and sclerosis of the choroidal vessels. BCD is rare in Caucasians but relatively common in Asian populations. After the genetic defect was initially linked to chromosome 4q35 (Jiao et al. 2000) , Li et al. identified bi-allelic mutations in the 'orphan' P450 enzyme, CYP4V2, in 23 out of 25 index patients from families with BCD. Numerous research groups (Gekka et al. 2005; Lin et al. 2005; Shan et al. 2005; Wada et al. 2005; Yokoi et al. 2010) have confirmed the original genetic findings (Kelly et al. 2011) . Importantly, a recent study demonstrated that more than 95% of all analyzed BCD patients have germ-line mutations in the CYP4V2 gene (Xiao et al. 2011) . Although more than 34 distinct mutations have been identified, variation in exons 6 to 9 account for >80% of all mutations with at least three founder mutations existing; c.802-8_810del17insGC, c.992A>C, and c.1091-2A>G that account for 62.7%, 7.4%, and 6.4%, respectively of all mutated alleles (Xiao, 2011) .
Although complex lipid deposits are also found in the circulating lymphocytes and skin fibroblasts of BCD patients (Wilson 1989; Kaiser-Kupfer et al. 1994 ) and expression of CYP4V2 mRNA has been detected in most human tissues (Li et al. 2004) , the clinical disease phenotype seems to be restricted to the eye. The composition of these crystalline lipids has not been elucidated, but early biochemical tracer studies were indicative of a cellular defect in the MOL #80085 5 anabolism of ω -3 polyunsaturated fatty acids (PUFAs) (Lee et al. 2001) . More recently, analysis of total fatty acids in the plasma of BCD patients relative to control subjects were suggestive of a defect in the synthesis of oleic acid (Lai et al. 2010) .
CYP4V2 is generally referred to as an 'orphan' P450 because its substrate specificity is just beginning to be defined (Kelly et al. 2011) . Typically, CYP4 enzymes are microsomal fatty acid ω -hydroxylases that function together with mitochondrial and peroxisomal α /β-oxidation enzymes to degrade cellular lipids. Although CYP4V2 is the most distantly related of all the human CYP4 enzymes, with a sequence identity of only ~35% (Rettie 2008) , we found recently that the recombinantly expressed enzyme possesses typical CYP4 ω -hydroxylase activity towards medium-chain saturated fatty acids (Nakano et al. 2009 ). Therefore, it is tempting to speculate that genetic defects in the catalytic function of CYP4V2 prevent local ocular degradation of lipids that subsequently accumulate in BCD.
For the foregoing scenario to be viable, we postulated that CYP4V2 should be expressed locally in BCD target tissues, and be capable of metabolizing key ocular lipids. No quantitative data on CYP4V2 expression are available (Li et al. 2004) , and no studies on protein expression in ocular tissues have been reported. Therefore, we analyzed the expression of CYP4V2 mRNA and protein in BCD target tissues and evaluated the functional activity of wild-type CYP4V2 and the most frequent coding-region BCD-associated mutation, p.H331P, with particular emphasis on the ability to process docosahexaenoic acid (DHA), which is found at high concentrations in the eye. We also stably expressed the wild-type and the mutant CYP4V2 enzymes in HepG2cells to evaluate enzyme translation/stability and effect on endogenous lipid profiles. 
RT-PCR analysis
Total RNA from ARPE-19 cells was isolated by using TRI Reagent® as described in the manufacturer's protocol (Applied Biosystems, Foster City, CA). The quality and quantity of the total RNA was determined spectrophotometrically. cDNA was synthesized from 1 μ g of the total RNA using MultiScribe™ Reverse Transcriptase with random hexamers in a total volume of 10μL. Real time RT-PCR reaction mixtures contained 0.1 μ g of cDNA, PCR Master Mix and Taqman gene expression probes (Applied Biosystems) for the following genes: human GusB, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4, CYP4A11, CYP4B1, CYP4F3, CYP4F12 and CYP4V2. Amplification reactions were done on an Applied Biosystems 7900 HT-SDS instrument for 40 cycles of 95˚C/15 sec, 60˚C/60 sec and Ct values determined using SDS V 2.3 software. The expression levels (ΔΔCt) were determined in relation to the house keeping gene GusB with CYP4V2 as a calibrator.
CYP4V2 expression, purification and quality control
Cloning and expression of CYP4V2 in insect cells were described previously (Nakano et al. 2009 ). The wild-type CYP4V2 protein was purified by Ni-NTA and hydroxyapatite (HA) columns, as described elsewhere (Cheesman et al. 2003 ) with minor modifications. The final product was dialyzed twice against 100mM potassium phosphate at pH7.4, 20% glycerol and 0.1 This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on July 6, 2012 as DOI: 10.1124/mol.112.080085 at ASPET Journals on June 20, 2017 molpharm.aspetjournals.org Downloaded from mM EDTA and stored at -80ºC. Purity was assessed by SDS-PAGE (9%) with Coomassie blue staining. Reduced carbon monoxide (CO)-bound spectra and absolute spectra were recorded on a Cary 300 UV/VIS Spectrometer (Nakano et al. 2009 ). The molecular weight of purified CYP4V2 was determined by LC-MS as previously described .
CYP4F2 expression and purification
The wild-type CYP4F2 gene was a kind gift from Drs. David E. Stec (University of Mississippi Medical Center, Jackson, MS) and Mark J. Rieder (University of Washington, Seattle, WA). To obtain the full length cDNA with the hexahistidine tag, CYP4F2 was amplified by PCR with the specific primers, 5'-GCG CGA ATT CAT GTC CCA GCT GAG CCT GTC CTG GC-3' and 5'-GCG CGT CGA CTC AAT GAT GAT GAT GAT GAT GGC TCA GGG GCT CCA CCC-3'. Preparation of a recombinant baculovirus containing CYP4F2 with a hexahistidine tag was generated using the Bac-to-Bac® Baculovirus expression system (Invitrogen, Carlsbad, CA) as described elsewhere (Nakano et al. 2009 ). CYP4F2 expression and purification were performed as described above for CYP4V2 with minor modifications.
Antibody production and assessment of cross-reactivity
Anti-CYP4V2 antibody production was carried out by R&R Research (Stanwood, WA) using purified CYP4V2 as the antigen. Briefly, two rabbits were immunized with the purified CYP4V2 protein supplemented with complete adjuvant along with 3 boosts (1 mg total). Twelve weeks after initial immunization, the animals were sacrificed and sera isolated. Polyclonal IgG was isolated from the crude sera of pre-and post-immunized animals following fractionation with a saturated ammonium sulfate solution. The cross reactivity of the anti-CYP4V2 IgG towards other CYP4 enzymes (Supersomes® and purified CYP4B1 expressed in E.coli) was determined MOL #80085 from Western blots of 0.2 pmol of purified CYP4V2, 1 pmol of Supersomes® (CYP4A11, CYP4F2, CYP4F3A, CYP4F3B, CYP4F12) and 1 pmol of purified rabbit CYP4B1.
Immunocytochemical staining
A detailed procedure can be found at http://www.abcam.com. Briefly, after fixing and blocking, ARPE-19 cells were incubated first with anti-CYP4V2 or pre-immune rabbit IgG and then with an anti-calreticulin antibody. The secondary antibody incubation was performed with a mixture of anti-rabbit IgG antibody conjugated with fluorescein (Pierce, Rockford, IL) and antimouse IgG antibody conjugated with Cy5®. The processed samples were analyzed using a Zeiss LSM 510 META instrument.
Immunohistochemical staining
Tissue sections were first deparaffinized, rehydrated and treated with sodium citrate buffer (10mM sodium citrate, 0.05% Tween-20, pH 6.0). Sections were then blocked with secondary antibody host serum, and treated with anti-CYP4V2 antibody or preimmune IgG followed by a secondary anti-rabbit antibody conjugated with alkaline phosphatase. The sections were visualized using Fast-Red and counterstained with hematoxylin.
DHA and EPA metabolic incubations
Purified CYP4V2 or CYP4F2 (200 pmol) was mixed with purified NADPH-cytochrome P450 reductase and cytochrome b 5 at a molar ratio of 1:2:1 or 1:3:4, respectively (Powell et al. 1998; Nakano et al. 2009 ). DLPC (8µg) and the substrates, dissolved in ethanol, were added and incubated on ice for 5 min. The mixture was made up to a total volume of 500 µL with 100 mM potassium phosphate buffer (pH 7.4) and pre-incubated for 2 min at 37˚C in a water bath. (Fer et al. 2008 ).
GC-CI/MS and GC-FID analysis of EPA and DHA metabolism
Derivatized extracts were analyzed on a Shimadzu QP2010 Gas Chromatograph quadrupole mass spectrometer fitted with a 12 m-fused silica capillary column (SPB-1), and operating in the chemical ionization (CI) mode. Derivatized analytes were injected at a temperature of 80ºC.
After 1 min, the oven temperature was raised at 70ºC/min to 200ºC, held for 1 min, then raised at 15ºC/min to 300ºC. Under these conditions, the derivatized ω and ω -1 hydroxylated metabolites of DHA (EPA) eluted at 8.8 (7.9) and 9.2 (8.3) min, respectively. To quantitate the formation of ω -hydroxylated metabolites of DHA and EPA, derivatized analytes were re-injected on a gas chromatograph with flame ionization detection (GC-FID) equipped as described above for the GC-MS analysis. Due to a lack of the authentic chemical standards, we constructed standard curves for quantitation with 22-hydroxydocosanoic acid and 20-hydroxyeicosanoic acid because these compounds possess the same carbon-chain lengths as ω -hydroxy DHA and ω -hydroxy This article has not been copyedited and formatted. The final version may differ from this version. ω -1 hydroxy EPA and DHA metabolites were not quantitated by GC-FID due to low signal intensities.
HepG2 cells stably expressing CYP4V2 and p.H331P.
The CYP4V2 WT and CYP4V2 H331P genes were amplified from pFastBac plasmids (Nakano et al., 2009 ) using the primers 5'-ACGCCTCGAGGCCACCATGGCGGGGCTCTGGCTGG-3' (forward) and 5'-GATCAAGTTGAAGAGGAGAAATGCAGATGAACGCTAAGGATCCGCGC-3' (reverse).
The PCR amplified products were cloned into the puc2CL6IN lentiviral vector using XhoI and BamHI in the multiple cloning sites. Next, HEK293T cells were transfected using polyethyleneimine transfection reagent with 6 µg each of an HIV1 helper plasmid pCD/NL-BH, expression construct for HIV1 gag/pol/rev (Mochizuki 1998) , the envelope vector (pczVSV-G) (Petschmann 1999) , and the vector plasmids puc2CL6IN, puc2CL6-4V2wtIN or puc2CL6-4V2H331PIN, respectively. Viral supernatants were harvested 48 hours after transfection, filtered through a 0.45 µm filter and used to transduce HepG2 cells. After 24 h, the transduced cells were selected with 1 mg/ml Genticin® for 7-10 days. The established cell lines were passaged at least 4 times before analysis.
Western blot analysis
CYP4V2 samples (10 µg of microsomal protein from Sf9 cells or 50 µg of total membranes from HepG2 cells) were mixed with Laemmli buffer containing 56 mg/mL DTT and boiled.
Samples were separated on 9% SDS-PAGE gels, transferred to nitrocellulose membranes, and the membranes blocked with Odyssey Blocking buffer containing 3% goat serum. Membranes were incubated with anti-CYP4V2 and/or mouse monoclonal anti-β-actin and washed with PBS containing 0.3% Tween-20 and incubated with anti-rabbit antibody conjugated with IR800 dye This article has not been copyedited and formatted. The final version may differ from this version. and/or anti-mouse antibody conjugated with IR680 dye. After washing with TPBS, the CYP4V2 and β -actin bands were visualized and quantitated using the Odyssey system (LI-COR Biosciences).
Lipid extraction and lipid profiling by GC-EI/MS
Harvested HepG2 cells were sonicated briefly. Cell lysate (500 µg) containing 1 µg of 2,2-d 2 -stearic acid (internal standard) was made up to a total volume of 500 µL with 100 mM potassium phosphate buffer (pH=7.4). Total lipid was extracted using methanol and methyl-tbutyl ether as described previously (Matyash et al. 2008 ). The extracted fraction was reconstituted with a small amount of ethyl acetate and transesterified with methanolic sulfuric acid (10%, v/v, Sigma-Aldrich). Transesterified lipids were analyzed on a Shimadzu QP2010 gas chromatograph quadrupole mass spectrometer fitted with a 60 m-fused silica capillary column (DB-1). The analytes were injected at a temperature of 100ºC. After 2 min, the oven temperature was raised at 30ºC/min to 130ºC, 10ºC/min to 180ºC, held for 2 min, 4ºC/min to 210ºC, 10ºC/min to 235ºC, held for 3 min, 4ºC/min to 255ºC, 10ºC/min to 310ºC, then held for 4 min.
Under these conditions, the derivatized saturated and unsaturated fatty acids were eluted as follow: d2-C18:0; 21.30 min, C14:0; 13.86 min, C16:0; 17.77 min, C16:1; 17.36 min, C18:0; 21.30 min, C18:1 cis-9; 20.91 min, C18:1 cis-11; 21.01 min, C20:4n-6; 23.66 min, C20:5n-3; 23.57 min and C22:6n-3; 27.65 min (Supplemental Table 1 expression in this cell line (Figure 1 ). In addition, we detected high expression of CYP1B1, which was transcribed at a similar level (88% of CYP4V2 mRNA expression) in these cells.
CYP2E1, CYP2J2 and CYP3A4 were transcribed only at low levels (5% of CYP4V2 mRNA expression) and transcripts for the other CYP4 genes, CYP4A11, CYP4B1, CYP4F2, CYP4F3
and CYP4F12 were not detectable (Figure 1 ).
CYP4V2 protein expression in ARPE-19 cells
To determine whether CYP4V2 protein along with its mRNA was abundant in ARPE-19 cells, we generated a highly specific polyclonal antibody against purified human CYP4V2 (see below). As proof of the specificity of the antibody, the cross reactivity of the CYP4V2 antibody towards other human CYP family 4 enzymes was determined by Western blotting. We used rabbit CYP4B1 prepared in our laboratory (87% sequence identity to human CYP4B1) because This article has not been copyedited and formatted. The final version may differ from this version. (Figure 2a ).
Next, we performed quantitative Western blotting on lysates of ARPE-19 cells. As shown in Figure 2b , CYP4V2 was readily detectable at levels that averaged 6 pmol/mg protein.
Immunocytochemical analysis further revealed that CYP4V2 co-localized with calreticulin (Supplemental Figure 1) , a well-characterized marker of endoplasmic reticulum. Therefore, CYP4V2 is expressed in ARPE-19 cells at a significant level and correctly localized to microsomal membranes.
Immunohistochemical analysis of human ocular tissues
As BCD patients exhibit crystal deposits mainly in the retina and the cornea, we utilized the endocrine organs all stained strongly positive for the CYP4V2 protein. We found strong expression in tissues and cells with a major role in fatty acid and steroid metabolism such as hepatocytes in liver, islet cells in pancreas, endothelium in hypophysis, prostate, adrenal gland, testis, breast and parathyroid, and glandular epithelium in uterus (Supplemental Table 2 ). To specifically analyze CYP4V2 expression in drug metabolizing tissues, microsomes were prepared from 4 individual kidneys, 4 small intestines and 9 livers, and examined by Western blot. As shown by Western blotting, (Supplemental Figure 3) , CYP4V2 protein was readily detectable in human liver, while only a negligible amount or no expression was found in human kidney or small intestine, respectively
Characterization of purified CYP4V2
To further characterize the biochemical activity of CYP4V2, His-tagged CYP4V2 was overexpressed in insect cells and isolated by nickel affinity and hydroxyapatite chromatography.
SDS-PAGE analysis revealed a single major band of ~60 kDa apparent molecular weight ( Figure   4a ), which was confirmed by LC-MS as 62,163 Da (data not shown). These experimentally determined values closely matched the calculated molecular weight of CYP4V2, with its heme prosthetic group covalently bound (62,160 Da) (Cheesman et al. 2003) . CYP4V2 was isolated mainly in its low spin form, as indicated by the prominent Soret band in the absolute oxidized spectrum at 419 nm and the minor α and β bands at 571 and 535 nm, respectively (Figure 4b ).
CYP4V2 displays a typical reduced-carbon monoxide P450 spectrum with a Soret maximum near 450 nm (Figure 4c ). No P420 was observed in the final enzyme preparation which had a specific content of 9.2 nmol/mg protein, indicating that >50% was holo-enzyme.
This article has not been copyedited and formatted. The final version may differ from this version. CYP4V2 metabolized DHA slightly more rapidly than did CYP4F2, and metabolized EPA at an equivalent rate.
Characterization of the CYP4V2 p.H331P variant:expression and functional activity
Finally, to evaluate the expression and functional consequences of the p.H331P mutation relative to wild-type CYP4V2, we expressed both enzymes in HepG2 cells using lentiviral expression vectors. mRNA analysis revealed comparable levels of expression for both the wildtype (4V2WT) and mutant (4V2H331P) transcripts (Figure 6a ). However, steady-state protein expression was much higher for wild-type CYP4V2 compared to the mutant (Figure 6b ). 
Discussion
Genetic defects in the cytochrome P450-dependent metabolism of endogenous substrates are recognized to underlie numerous diseases states. For example, steroid metabolism defects due to mutations in CYP7B1, CYP11A1 and CYP17A1 cause spastic paraplegia type 5, lipoid adrenal hyperplasia and mineralocorticoid excess syndromes, respectively (Nebert 2002; Russell et al. 2009 ). In terms of ocular disease, mutations in CYP1B1 are a well-established cause of primary congenital glaucoma (Sarfarazi et al. 1995; Stoilov et al. 1997) , although other loci, notably LTBP2, appear to be involved in development of the disease (Ali et al. 2009 ). In contrast, mutations in CYP4V2 are singularly associated with BCD, a situation that provides experimental opportunities for deciphering the endogenous substrate(s) for the enzyme and perhaps also for shedding light on the pathophysiology of BCD.
If CYP4V2 plays a significant metabolic role in BCD, it seems important that the enzyme be localized to target tissue(s) of BCD. CYP2A6 and CYP2C8 mRNA have been identified previously from tissue homogenates of human retina/choroid by RT-PCR (Zhang et al. 2008) , and expression of CYP4V2 mRNA in the retina and in RPE cells has been reported, but no quantitative data are available (Li et al. 2004) . In the present study, we found CYP4V2 and CYP1B1 to by far the most highly expressed P450 mRNAs in ARPE-19 cells. In fact, of 15 other P450s that were analyzed, only mRNA for CYP2E1, CYP2J2 and CYP3A4 were quantifiable, and these levels reached <10% that of CYP4V2. CYP4A and CYP4F are expressed at significant levels in human liver and, especially the kidney where they are believed to have important roles in 20-HETE formation (Lin et al. 1994; Zou et al. 1994; Carroll et al. 1997) . In marked contrast, the mRNA data from ARPE-19 cells suggest that these more commonly studied CYP4 enzymes may be functionally silent in these naturally transformed human RPE cells.
Additionally, to facilitate analysis of CYP4V2 protein expression, we expressed and purified the recombinant enzyme to generate a highly selective polyclonal antibody for Western blotting and immunohistochemical analysis of target tissues in BCD. CYP4V2 protein was readily detected in human retinal epithelium and the endoplasmic reticulum of ARPE-19 cells, and to a lesser extent in corneal epithelium. Therefore, CYP4V2 is clearly present in ocular cells that are affected in BCD, and may be the dominant functional CYP4 enzyme at these sites. These studies establish ARPE-19 cells as an important tool for evaluating BCD-related biochemical changes in a disease-relevant cell line following knock-down of the endogenous enzyme.
We demonstrated previously that baculovirus-mediated expression of CYP4V2 in insect cells yielded a metabolically competent ω -hydroxylase of several saturated fatty acids that was sensitive to inhibition by HET0016 at nanomolar concentrations (Nakano et al. 2009 ). Therefore, despite its low sequence identity with other human CYP4 enzymes, CYP4V2 exhibits their prototypic functional characteristics. In the present study we purified CYP4V2 to near homogeneity and found that the recombinant enzyme was isolated from this expression system in the low-spin (ligand-free) state. Therefore, to further probe the substrate specificity of the enzyme, we turned our attention to fatty acids that are present at high concentrations in the retina.
The physiology of the retina has been studied extensively; photoreceptor cells, rods and EPA (C20:5n-3) is a minor retinal lipid (Anderson 1970) . In fact, DHA in the rod outer segment (ROS) of rats represents ~50% of the total fatty acids esterified to phosphatidylethanolamine and phosphatidylserine (Fliesler 1983) . The ROS together with RPE cells, possess an efficient lipid recycling system in order to regenerate disk membranes and maintain a high PUFA content (Bazan 2006) . Notably, ten percent of the ROS is renewed daily in primates (Young 1967; Young 1971) , and the rates of synthesis and disposal of disk membranes are about the same under normal conditions in mice (Young 1971; LaVail 1973) . Because DHA homeostasis is so tightly regulated in RPE cells, we compared the substrate specificity of CYP4V2 towards the
PUFAs, EPA and DHA.
ω -3 PUFAs would be expected to undergo rate-limiting CYP4-dependant ω -oxidation followed by β -oxidation in peroxisomes and mitochondria (Hardwick 2008) . CYP4F family enzymes, principally CYP4F2 and CYP4F3B, have been reported to be the main PUFA hydroxylases in human liver (Fer et al. 2008) . The current study extends the repertoire of PUFA hydroxylases to CYP4V2, which we found to preferentially catalyze ω - and ω -1 hydroxylation of both EPA and DHA. Purified CYP4V2 and CYP4F2 metabolized both PUFAs at similar rates, but since CYP4F enzymes were not expressed at a significant level in ARPE-19 cells (or corneal CRL11515 cells, data not shown), CYP4V2 is likely to dominate CYP4-dependent PUFA catalysis in BCD target tissues in the eye. Moreover, CYP4V2 is expressed at readily detectable levels in human liver and so, in some subjects, the enzyme may also be a contributor to hepatic metabolism of ω -3 PUFAs. However, further studies are needed to test this hypothesis.
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